CannapharmaRX Updates on Alberta Facility Progress and International Export Strategy
03.12.2024CannaPharmaRX, Inc. (OTC PINK:CPMD), a future leader in cannabis cultivation, is steadily advancing its position in high-efficiency cannabis production. The Company is excited to share its latest updates with shareholders and prospective investors, highlighting its substantial progress, current operations, and future growth plans.
Advanced Production Facility in Alberta
CannaPharmaRX’s advanced facility in Alberta houses 10 growing rooms designed for maximum efficiency and yield. Each room produces an average harvest of 130 kilograms, comprising approximately 95 kilograms of premium flowers and 35 kilograms of trim products, all within an 8-10-week harvest cycle.
Currently, the Company operates four active growing rooms and plans to add another in December, enabling a bi-weekly harvest schedule. This operational strategy translates to an estimated monthly production of 210 kilograms of flower and 77 kilograms of trim, ensuring a steady supply for its growing customer base.
Revenue Projections
The Company’s non-branded cannabis products are competitively priced at 1.9 – 2.2 CAD per gram for flowers and 0.1 – 0.2 CAD per gram for trim. With strong demand, CannaPharmaRX is projected to generate approximately 430,000 CAD in monthly revenue, with current orders accounting for the entire yield. Looking ahead to late 2025, the planned launch of branded cannabis products is expected to further drive profitability, with flower prices projected to reach up to 3 CAD per gram.
Global Export Initiatives
CannaPharmaRX is making progress in international markets, with upcoming shipments planned for:
December 2024: 245.7 kilograms to Israel
January 2025: Approximately 385 kilograms
Additionally, the Company is leveraging partnerships with third-party farms, enabling the shipment of 72 kilograms of cannabis to customers in Israel in exchange for a 5-10% commission.
To expand its global footprint, CannaPharmaRX is conducting a feasibility study targeting exports to Europe, with a particular focus on Germany.
Growth Plans for 2025
To optimize production and meet increasing demand, CannaPharmaRX is exploring the construction of an additional drying room. This development would support a one-week harvest cycle across all 10 growing rooms. The Company also plans to launch its branded cannabis products in 2025, aiming to strengthen its position as a premium provider.
Short and long-term liabilities
A strategic plan for 2025 is being developed to reduce long-term debt and strengthen the company’s financial position and to keep current in its short-term obligations.
New CEO
To drive its vision of international expansion and innovation, CannaPharmaRX is actively seeking a CEO with global expertise. This new leadership role is key to advancing the company’s goals and scaling operations internationally.
CTO
In compliance with Canadian regulations, CannaPharmaRX is actively engaging with local authorities to lift the cease trade orders from BCSC.
Cautionary Note Regarding Forward-Looking Information or Statements
This press release contains forward-looking information or statements. All statements that are or information which is not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are ‘forward-looking information or statements.’ Forward-looking information or statements can be identified by the use of words such as ‘plans,’ ‘expects,’ or ‘does not expect,’ ‘is expected,’ ‘estimates,’ ‘intends,’ ‘anticipates,’ or ‘does not anticipate,’ or ‘believes,’ or variations of such words and phrases or statements that certain actions, events or results ‘may,’ ‘could,’ ‘would,’ ‘might’ or ‘will’ be taken, occur or be achieved. With respect to forward-looking information and statements contained herein, Management of CannapharmaRx has made numerous assumptions, including, among other things, assumptions about general business and economic conditions. Such forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from any future results, events, or developments expressed or implied by such forward-looking information or statements. Readers are cautioned not to place undue reliance on such forward-looking information or statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking information or statements. CannapharmaRx assumes no obligation to update any forward-looking information or statements, even if new information becomes available as a result of future events, new information, or for any other reason except as required by law.